IONIS Pharmaceuticals stock shows strong technical and fundamental momentum, meeting strict trend-following criteria with surging earnings and revenue growth.
Carlsbad, CA – October 8, 2025 – Ionis Pharmaceuticals (NASDAQ:IONS) is currently witnessing a remarkable surge in its stock value, nearing a six-year high. This impressive ascent is largely driven by the company's recent strategic guidance, which forecasts over $5 billion in potential annual peak sales from its robust pipeline of
In two studies, Ionis’ Olezarsen demonstrated a highly statistically significant placebo-adjusted mean reduction in fasting triglycerides of up to 72% at six months.
Ionis posted positive Phase 3 results for olezarsen in severe hypertriglyceridemia, showing 72% triglyceride reduction and 85% fewer pancreatitis events.
The session on Tuesday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.
